Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R. Gandara, David S. Shames, Wei Zou et al.|Nature Medicine|2018Cited by 1.2k
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancerNamrata S. Patil, David S. Shames, Barzin Y. Nabet et al.|Cancer Cell|2022Cited by 403